

Eva Segelov

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/4507321/eva-segelov-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

121
papers

1,960
citations

24
h-index

41
g-index

134
ext. papers

2,524
ext. citations

4.2
avg, IF

4.67
L-index

#	Paper	IF	Citations
121	Protocol for SARS-CoV-2 post-vaccine surveillance study in Australian adults and children with cancer: an observational study of safety and serological and immunological response to SARS-CoV-2 vaccination (SerOzNET).. <i>BMC Infectious Diseases</i> , 2022 , 22, 70	4	0
120	COVID-19 vaccination rates, intent, and hesitancy in patients with solid organ and blood cancers: A multicenter study.. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2022 ,	1.9	2
119	Excellent Response to MEK Inhibition in an Gene Fusion Driven Carcinoma: Case Report and Literature Review.. <i>Anticancer Research</i> , 2022 , 42, 373-379	2.3	0
118	Global Oncology Authorship and Readership Patterns.. <i>JCO Global Oncology</i> , 2022 , 8, e2100299	3.7	0
117	A Machine-Learning-Based Bibliometric Analysis of the Scientific Literature on Anal Cancer.. <i>Cancers</i> , 2022 , 14,	6.6	2
116	The Management of Unresectable, Advanced Gastrointestinal Stromal Tumours.. <i>Targeted Oncology</i> , 2022 , 17, 95	5	1
115	"Global Multidisciplinary Team Meetings": Challenging Cases Virtual Forums from the International Multidisciplinary Anal Cancer Conference (IMACC).. <i>Clinical Colorectal Cancer</i> , 2022 ,	3.8	1
114	Barriers and enablers to cancer clinical trial participation and initiatives to improve opportunities for rural cancer patients: A scoping review.. <i>Clinical Trials</i> , 2022 , 17407745221090733	2.2	0
113	Serious Underlying Medical Conditions and COVID-19 Vaccine Hesitancy: A Large Cross-Sectional Analysis from Australia. <i>Vaccines</i> , 2022 , 10, 851	5.3	0
112	Dihydropyrimidine dehydrogenase deficiency in patients with severe toxicity after 5-fluorouracil: a retrospective single-center study. <i>Annals of Gastroenterology</i> , 2021 , 34, 68-72	2.2	0
111	Update on optimal management for pancreatic cancer: expert perspectives from members of the Australasian Gastrointestinal Trials Group (AGITG) with invited international faculty. <i>Expert Review of Anticancer Therapy</i> , 2021 , 1-13	3.5	
110	Patients' Preferences for 3 Months vs 6 Months of Adjuvant Chemotherapy for Colon Cancer. <i>JNCI Cancer Spectrum</i> , 2021 , 5, pkaa107	4.6	0
109	COVID-19 vaccinations for patients with cancer: many remain unvaccinated despite having priority in the vaccine rollout. <i>Internal Medicine Journal</i> , 2021 , 51, 1760	1.6	0
108	Effect of Fractional Carbon Dioxide Laser vs Sham Treatment on Symptom Severity in Women With Postmenopausal Vaginal Symptoms: A Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , 2021 , 326, 1381-1389	27.4	16
107	Pituitary function following peptide receptor radionuclide therapy for neuroendocrine tumours. <i>Cancer Medicine</i> , 2021 , 10, 8405-8411	4.8	3
106	Neoadjuvant Therapy for Locally Advanced Rectal Cancer: Recent Advances and Ongoing Challenges. <i>Clinical Colorectal Cancer</i> , 2021 , 20, 29-41	3.8	3
105	The Role of Neoadjuvant Chemotherapy in Locally Advanced Colon Cancer. <i>Cancer Management and Research</i> , 2021 , 13, 2567-2579	3.6	4

104	Whole blood expression as a prognostic biomarker in metastatic hormone-sensitive and castration-resistant prostate cancer. <i>Translational Andrology and Urology</i> , 2021 , 10, 1688-1699	2.3	
103	Developing clinical indicators for oncology: the inaugural cancer care indicator set for the Australian Council on Healthcare Standards. <i>Medical Journal of Australia</i> , 2021 , 214, 528-531	4	1
102	Medical Oncology Group of Australia position statement: COVID-19 vaccination in patients with solid tumours. <i>Internal Medicine Journal</i> , 2021 , 51, 955-959	1.6	1
101	Cancer care disparities among Australian and Aotearoa New Zealand Indigenous peoples. <i>Current Opinion in Supportive and Palliative Care</i> , 2021 , 15, 162-168	2.6	0
100	Anti-cancer therapy made easier: a 25-year update. <i>Internal Medicine Journal</i> , 2021 , 51, 473-480	1.6	2
99	AMTRA: a multicentered experience of a web-based monitoring and tailored toxicity management system for cancer patients. <i>Supportive Care in Cancer</i> , 2021 , 29, 859-867	3.9	7
98	An update on the use of immunotherapy in patients with colorectal cancer. <i>Expert Review of Gastroenterology and Hepatology</i> , 2021 , 15, 291-304	4.2	8
97	Prognostic Utility of a Whole-blood Androgen Receptor-based Gene Signature in Metastatic Castration-resistant Prostate Cancer. <i>European Urology Focus</i> , 2021 , 7, 63-70	5.1	6
96	The EUS molecular evaluation of pancreatic cancer: A prospective multicenter cohort trial. <i>Endoscopic Ultrasound</i> , 2021 , 10, 335-343	3.6	1
95	MONARCC: a randomised phase II study of panitumumab monotherapy and panitumumab plus 5-fluorouracil as first-line therapy for RAS and BRAF wildtype metastatic colorectal cancer: a study by the Australasian Gastrointestinal Trials Group (AGITG). <i>BMC Cancer</i> , 2021 , 21, 932	4.8	1
94	Treatment of Squamous Cell Carcinoma of the Anus, Unresolved Areas and Future Perspectives for Research: Perspectives of Research Needs in Anal Cancer. <i>Clinical Colorectal Cancer</i> , 2021 ,	3.8	2
93	Three Versus Six Months of Adjuvant Doublet Chemotherapy for Patients With Colorectal Cancer: A Multi-Country Cost-Effectiveness and Budget Impact Analysis. <i>Clinical Colorectal Cancer</i> , 2021 , 20, 236-244	2.8	1
92	Practical Considerations for Treating Patients With Cancer in the COVID-19 Pandemic. <i>JCO Oncology Practice</i> , 2020 , 16, 467-482	2.3	37
91	A 2020 update of anal cancer: the increasing problem in women and expanding treatment landscape. <i>Expert Review of Gastroenterology and Hepatology</i> , 2020 , 14, 665-680	4.2	4
90	International Rare Cancers Initiative Multicenter Randomized Phase II Trial of Cisplatin and Fluorouracil Versus Carboplatin and Paclitaxel in Advanced Anal Cancer: InterAAct. <i>Journal of Clinical Oncology</i> , 2020 , 38, 2510-2518	2.2	37
89	The prognostic role of inflammatory markers in patients with metastatic colorectal cancer treated with bevacizumab: A translational study [ASCENT]. <i>PLoS ONE</i> , 2020 , 15, e0229900	3.7	9
88	Update on optimal treatment for metastatic colorectal cancer from the AGITG expert meeting: ESMO congress 2019. <i>Expert Review of Anticancer Therapy</i> , 2020 , 20, 251-270	3.5	3
87	Management of early-stage gastro-esophageal cancers: expert perspectives from the Australasian Gastrointestinal Trials Group (AGITG) with invited international faculty. <i>Expert Review of Anticancer Therapy</i> , 2020 , 20, 305-324	3.5	

86	Medical Oncologists' Perspectives on How the Results of the IDEA Collaboration Impact the Adjuvant Treatment of Stage III Colon Cancer. <i>Oncologist</i> , 2020 , 25, 229-234	5.7	5
85	The Economic Impact on Australian Patients with Neuroendocrine Tumours. <i>Patient</i> , 2020 , 13, 363-373	3.7	8
84	Australian experience of peptide receptor radionuclide therapy in lung neuroendocrine tumours. <i>Oncotarget</i> , 2020 , 11, 2636-2646	3.3	5
83	Circulating epigenetic biomarkers for detection of recurrent colorectal cancer. <i>Cancer</i> , 2020 , 126, 1460-1469	14.9	18
82	Adjuvant anti-VEGF therapy for overall survival and relapse-free survival in patients with resected non-metastatic colorectal cancer. <i>The Cochrane Library</i> , 2020 ,	5.2	78
81	Towards new models of cancer care in Australia: lessons from Victoria's response to the COVID-19 pandemic. <i>Internal Medicine Journal</i> , 2020 , 50, 1282-1285	1.6	4
80	Refractory Metastatic Colorectal Cancer: Current Challenges and Future Prospects. <i>Cancer Management and Research</i> , 2020 , 12, 5819-5830	3.6	5
79	Commonwealth Neuroendocrine Tumour Research Collaboration and the North American Neuroendocrine Tumor Society Guidelines for the Diagnosis and Management of Patients With Lung Neuroendocrine Tumors: An International Collaborative Endorsement and Update of the 2015 European Neuroendocrine Tumor Society Expert Consensus Guidelines. <i>Journal of Thoracic</i>	8.9	26
78	Management of Asymptomatic Sporadic Nonfunctioning Pancreatic Neuroendocrine Neoplasms (ASPEN) \geq 1 cm: Study Protocol for a Prospective Observational Study. <i>Frontiers in Medicine</i> , 2020 , 7, 598438	4.9	7
77	Supportive oncofertility care, psychological health and reproductive concerns: a qualitative study. <i>Supportive Care in Cancer</i> , 2020 , 28, 809-817	3.9	8
76	Impact of the COVID-19 Epidemic on a Pan-Asian Academic Oncology Clinical Trial. <i>JCO Global Oncology</i> , 2020 , 6, 585-588	3.7	7
75	Consensus-Derived Quality Performance Indicators for Neuroendocrine Tumour Care. <i>Journal of Clinical Medicine</i> , 2019 , 8,	5.1	2
74	Physical Activity for Symptom Management in Women With Metastatic Breast Cancer: A Randomized Feasibility Trial on Physical Activity and Breast Metastases. <i>Journal of Pain and Symptom Management</i> , 2019 , 58, 929-939	4.8	18
73	Multifocal hepatic steatosis mimicking malignancy in two siblings. <i>JGH Open</i> , 2019 , 3, 346-348	1.8	0
72	Performance comparison of the methylated BCAT1/IKZF1 ctDNA test (COLVERA) with the CEA assay for detection of recurrent colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 3589-3589	2.2	2
71	Whole blood FOLH1 mRNA expression and treatment response in metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 188-188	2.2	
70	Phase II trial PD-L1/PD-1 blockade avelumab with chemoradiotherapy for locally advanced resectable T3B-4/N1-2 rectal cancer: The Ave-Rec trial.. <i>Journal of Clinical Oncology</i> , 2019 , 37, TPS3622-TPS3622	2.2	1
69	Integrative molecular analysis of colorectal cancer and gastric cancer: What have we learnt?. <i>Cancer Treatment Reviews</i> , 2019 , 73, 31-40	14.4	9

68	Adjuvant therapy for resected colon cancer 2017, including the IDEA analysis. <i>Expert Review of Anticancer Therapy</i> , 2018 , 18, 339-349	3.5	6
67	Immunohistochemistry testing for mismatch repair deficiency in Stage 2 colon cancer: A cohort study of two cancer centres. <i>International Journal of Surgery</i> , 2018 , 51, 71-75	7.5	4
66	Recurrence in Resected Gastroenteropancreatic Neuroendocrine Tumors. <i>JAMA Oncology</i> , 2018 , 4, 583-584	3.5	35
65	Follow-Up for Resected Gastroenteropancreatic Neuroendocrine Tumours: A Practice Survey of the Commonwealth Neuroendocrine Tumour Collaboration (CommNETS) and the North American Neuroendocrine Tumor Society (NANETS). <i>Neuroendocrinology</i> , 2018 , 107, 32-41	5.6	6
64	Influence of Population Immunosuppression and Past Vaccination on Smallpox Reemergence. <i>Emerging Infectious Diseases</i> , 2018 , 24, 646-653	10.2	15
63	Follow-up Recommendations for Completely Resected Gastroenteropancreatic Neuroendocrine Tumors. <i>JAMA Oncology</i> , 2018 , 4, 1597-1604	13.4	50
62	Targeted therapy for metastatic colorectal cancer. <i>Expert Review of Anticancer Therapy</i> , 2018 , 18, 991-1006	3.6	31
61	Effect of Primary Tumor Side on Survival Outcomes in Untreated Patients With Metastatic Colorectal Cancer When Selective Internal Radiation Therapy Is Added to Chemotherapy: Combined Analysis of Two Randomized Controlled Studies. <i>Clinical Colorectal Cancer</i> , 2018 , 17, e617-e629	3.8	31
60	Cetuximab Alone or With Irinotecan for Resistant KRAS-, NRAS-, BRAF- and PIK3CA-wild-type Metastatic Colorectal Cancer: The AGITG Randomized Phase II ICECREAM Study. <i>Clinical Colorectal Cancer</i> , 2018 , 17, 313-319	3.8	6
59	Patients' preferences for 3 months versus 6 months of adjuvant chemotherapy (ACT) for colon cancer in the SCOT trial: what survival benefits make longer chemotherapy worthwhile?. <i>Journal of Clinical Oncology</i> , 2018 , 36, 3602-3602	2.2	3
58	The prognostic role of inflammatory markers in patients with metastatic colorectal cancer treated with bevacizumab.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 719-719	2.2	3
57	COX2 and HLA immunohistochemical (IHC) staining in colorectal tumour samples from patients participating in the ASCOLT clinical trial of adjuvant aspirin therapy.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 695-695	2.2	
56	The commonwealth neuroendocrine tumour collaboration (CommNETs) and North American neuroendocrine tumor society (NANETS) endorsement and update of European neuroendocrine tumor society (ENETS) best practice consensus for lung neuroendocrine tumors (LNET). <i>Annals of Oncology</i> , 2018 , 29, viii-473	10.3	2
55	SCOT: a comparison of cost-effectiveness from a large randomised phase III trial of two durations of adjuvant Oxaliplatin combination chemotherapy for colorectal cancer. <i>British Journal of Cancer</i> , 2018 , 119, 1332-1338	8.7	9
54	Long-term Outcomes of Gastroenteropancreatic Neuroendocrine Tumors. <i>Pancreas</i> , 2018 , 47, 321-325	2.6	18
53	Randomized Evaluation of Cognitive-Behavioral Therapy and Graded Exercise Therapy for Post-Cancer Fatigue. <i>Journal of Pain and Symptom Management</i> , 2017 , 54, 74-84	4.8	29
52	The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Midgut Neuroendocrine Tumors. <i>Pancreas</i> , 2017 , 46, 707-714	2.6	152
51	Everolimus in the management of metastatic neuroendocrine tumours. <i>Therapeutic Advances in Gastroenterology</i> , 2017 , 10, 132-141	4.7	26

50	Current challenges in optimizing systemic therapy for patients with pancreatic cancer: expert perspectives from the Australasian Gastrointestinal Trials Group (AGITG) with invited international faculty. <i>Expert Review of Anticancer Therapy</i> , 2017 , 17, 951-964	3.5	1
49	Escalated-dose somatostatin analogues for antiproliferative effect in GEPNETS: a systematic review. <i>Endocrine</i> , 2017 , 57, 366-375	4	23
48	First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials. <i>Lancet Oncology</i> , 2017 , 18, 1159-1171	21.7	193
47	Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer. <i>The Cochrane Library</i> , 2017 , 6, CD007047	5.2	42
46	Identifying and Prioritizing Gaps in Neuroendocrine Tumor Research: A Modified Delphi Process With Patients and Health Care Providers to Set the Research Action Plan for the Newly Formed Commonwealth Neuroendocrine Tumor Collaboration. <i>Journal of Global Oncology</i> , 2017 , 3, 380-388	2.6	3
45	Uncommon Anal Neoplasms. <i>Surgical Oncology Clinics of North America</i> , 2017 , 26, 143-161	2.7	7
44	Results of the Quad wild type arm of the AGITG ICECREAM study: A randomised phase II study of cetuximab alone or in combination with irinotecan in patients with refractory metastatic colorectal cancer with no mutations in KRAS, NRAS, BRAF or PIK3CA.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 3572-3572	2.2	1
43	Development of follow up recommendations for completely resected gastroenteropancreatic neuroendocrine tumours (GEP-NETS): Practice Survey of Commonwealth Neuroendocrine Tumour Collaboration (CommNETS) in conjunction with North American Neuroendocrine Tumour Society (NANETS). <i>Journal of Clinical Oncology</i> , 2017 , 35, 224-224	2.2	
42	Escalated dose somatostatin analogues (SSAs) in management of neuroendocrine tumors (NETs): A systematic review.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 422-422	2.2	
41	JRK is a positive regulator of Eatenin transcriptional activity commonly overexpressed in colon, breast and ovarian cancer. <i>Oncogene</i> , 2016 , 35, 2834-41	9.2	14
40	Adjuvant capecitabine plus bevacizumab versus capecitabine alone in patients with colorectal cancer (QUASAR 2): an open-label, randomised phase 3 trial. <i>Lancet Oncology</i> , 2016 , 17, 1543-1557	21.7	94
39	ICECREAM: randomised phase II study of cetuximab alone or in combination with irinotecan in patients with metastatic colorectal cancer with either KRAS, NRAS, BRAF and PI3KCA wild type, or G13D mutated tumours. <i>BMC Cancer</i> , 2016 , 16, 339	4.8	11
38	Update on optimal treatment for metastatic colorectal cancer from the ACTG/AGITG expert meeting: ECCO 2015. <i>Expert Review of Anticancer Therapy</i> , 2016 , 16, 557-71	3.5	2
37	Diagnosis and management of gastrointestinal neuroendocrine tumors: An evidence-based Canadian consensus. <i>Cancer Treatment Reviews</i> , 2016 , 47, 32-45	14.4	57
36	Response to Cetuximab With or Without Irinotecan in Patients With Refractory Metastatic Colorectal Cancer Harboring the KRAS G13D Mutation: Australasian Gastro-Intestinal Trials Group ICECREAM Study. <i>Journal of Clinical Oncology</i> , 2016 , 34, 2258-64	2.2	41
35	Does the Chemotherapy Backbone Impact on the Efficacy of Targeted Agents in Metastatic Colorectal Cancer? A Systematic Review and Meta-Analysis of the Literature. <i>PLoS ONE</i> , 2015 , 10, e0135399	3.7	19
34	InterAACT: An international multicenter open label randomized phase II advanced anal cancer trial comparing cisplatin (CDDP) plus 5-fluorouracil (5-FU) versus carboplatin (CBDCA) plus weekly paclitaxel (PTX) in patients with inoperable locally recurrent (ILR) or metastatic disease.. <i>Journal of Clinical Oncology</i> , 2015 , 33, TPS792-TPS792	2.2	5
33	The role of biological therapy in metastatic colorectal cancer after first-line treatment: a meta-analysis of randomised trials. <i>British Journal of Cancer</i> , 2014 , 111, 1122-31	8.7	23

32	Loss of special AT-rich sequence-binding protein 1 (SATB1) predicts poor survival in patients with colorectal cancer. <i>Histopathology</i> , 2014 , 65, 155-63	7.3	29
31	A case-control study of the role of human papillomavirus in oesophageal squamous cell carcinoma in australia. <i>Journal of Oncology</i> , 2014 , 2014, 236482	4.5	5
30	Physical activity and fitness in women with metastatic breast cancer. <i>Journal of Cancer Survivorship</i> , 2014 , 8, 647-56	5.1	44
29	Current opinion on optimal systemic treatment for metastatic colorectal cancer: outcome of the ACTG/AGITG expert meeting ECCO 2013. <i>Expert Review of Anticancer Therapy</i> , 2014 , 14, 1477-93	3.5	12
28	Impact of chemotherapy partner on efficacy of targeted therapy in metastatic colorectal cancer (mCRC): A meta-analysis.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 3552-3552	2.2	2
27	Meta-analysis of outcomes of VEGF and EGFR targeted biologic therapy in relapsed metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 534-534	2.2	1
26	Cost-effectiveness of aspirin adjuvant therapy in early stage colorectal cancer in older patients. <i>PLoS ONE</i> , 2014 , 9, e107866	3.7	3
25	Prospective evaluation of KRAS, NRAS, BRAF, and PI3KCA mutation screening for patient enrolment in AGITG ICECREAM (Irinotecan Cetuximab Evaluation and the Cetuximab Response Evaluation among Patients with G13D Mutation) trial in metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2014 , 32, e14536-e14536	2.2	
24	Improving the impact of didactic resident training with online spaced education. <i>ANZ Journal of Surgery</i> , 2013 , 83, 477-80	1	15
23	Role of human papillomaviruses in esophageal squamous cell carcinoma. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2013 , 9, 12-28	1.9	21
22	Current opinion on optimal treatment for colorectal cancer. <i>Expert Review of Anticancer Therapy</i> , 2013 , 13, 597-611	3.5	24
21	The aetiological role of human papillomavirus in oesophageal squamous cell carcinoma: a meta-analysis. <i>PLoS ONE</i> , 2013 , 8, e69238	3.7	50
20	The Relationship between Human Papillomavirus and Oesophageal Squamous Cell Carcinoma in China: A Review of the Evidence. <i>Advances in Infectious Diseases</i> , 2013 , 03, 17-34	0.9	
19	Physical activity and fitness in women with metastatic breast cancer.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 136-136	2.2	
18	Pilot study evaluating the role of cardiac magnetic resonance imaging in monitoring adjuvant trastuzumab therapy for breast cancer. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2012 , 8, 95-100	1.9	24
17	Identifying and prioritising gaps in colorectal cancer trials research in Australia. <i>Medical Journal of Australia</i> , 2012 , 197, 507-11	4	7
16	Management of advanced gastric cancer. <i>Expert Review of Gastroenterology and Hepatology</i> , 2012 , 6, 199-208; quiz 209	4.2	61
15	High-risk human papillomavirus in esophageal squamous cell carcinoma--letter. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2011 , 20, 408; author reply 409-10	4	2

14	Current Opinion on Optimal Treatment Choices in First-line Therapy for Advanced or Metastatic Colorectal Cancer: Report From the Adelaide Colorectal Tumour Group Meeting; Stockholm, Sweden; September 2008. <i>Clinical Colorectal Cancer</i> , 2010 , 9, 8-14	3.8	7
13	Reasons to try 'RIME'. <i>Medical Education</i> , 2007 , 41, 1104	3.7	2
12	The emperor's new clothes - can chemotherapy survive?. <i>Australian Prescriber</i> , 2006 , 29, 2-3	1.4	2
11	Off-trial evaluation of bisphosphonates in patients with metastatic breast cancer. <i>BMC Cancer</i> , 2005 , 5, 89	4.8	11
10	PTEN mutations are common in sporadic microsatellite stable colorectal cancer. <i>Oncogene</i> , 2004 , 23, 617-28	9.2	122
9	Alterations of the Birt-Hogg-Dubé gene (BHD) in sporadic colorectal tumours. <i>Journal of Medical Genetics</i> , 2003 , 40, 511-5	5.8	27
8	Mechanisms determining sensitivity to cisplatin in three mutant Chinese hamster ovary cell lines. <i>Mutation Research DNA Repair</i> , 1998 , 407, 243-52		4
7	Long term response to chemotherapy in patients with visceral metastatic melanoma. <i>Annals of Oncology</i> , 1994 , 5, 249-51	10.3	24
6	Cisplatin-based chemotherapy for ovarian germ cell malignancies: the Australian experience. <i>Journal of Clinical Oncology</i> , 1994 , 12, 378-84	2.2	59
5	Chemotherapy made easier. <i>Australian and New Zealand Journal of Medicine</i> , 1993 , 23, 387-92		3
4	Acute leukaemia following chemotherapy including etoposide for testicular carcinoma. <i>Australian and New Zealand Journal of Medicine</i> , 1993 , 23, 718-9		4
3	The impact of histological review on clinical management of testicular cancer. <i>British Journal of Urology</i> , 1993 , 71, 736-8		21
2	Risk factors, epidemiology, screening, and prognostic factors in female genital cancer. <i>Current Opinion in Oncology</i> , 1992 , 4, 913-22	4.2	9
1	Redressing the balance--the ethics of not entering an eligible patient on a randomised clinical trial. <i>Annals of Oncology</i> , 1992 , 3, 103-5	10.3	27